Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100242 · ClinicalTrials.gov registry record · Phase 2
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01100242 is a Phase 2 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 17 participants.
The verdict
NCT01100242, a Phase 2 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is an open label, non-randomized, single arm phase II study. The primary objective of this study is to investigate the efficacy of combination of sorafenib and VELCADE® (bortezomib). The primary efficacy endpoint is Progression-Free Survival (PFS). The secondary objectives of this study are to: Assess the response rate of this combination in this patient population and Assess the toxicity of this combination in this patient population
Interventions
- DRUG Velcade and Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-04 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100242
The ClinicalTrials.gov registry entry for NCT01100242 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Velcade and Sorafenib is the first listed.
NCT01100242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01100242 about?
NCT01100242 is a clinical study titled "Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma". This is an open label, non-randomized, single arm phase II study. The primary objective of this study is to investigate the efficacy of combination of sorafenib and VELCADE® (bortezomib). The primary efficacy endpoint is Progression-Free Survival (PFS). The secondary objectives of this study are to:...
What is the current status of trial NCT01100242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-04. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01100242?
The interventions under investigation include: Velcade and Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01100242?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.